

# MIKKA

## FIRMING NIGHT CREAM



Ingredients: AQUA, PRUNUS AMYGDALUS DULCIS OIL, HAMAMELIS VIRGINIANA LEAF WATER, ARGANIA SPINOSA KERNEL OIL, COCOS NUCIFERA OIL, BUTYROSPERMUM PARKII BUTTER, CETEARYL ALCOHOL, CETEARYL GLUCOSIDE, GLYCERIN, PANTHENOL, TOCOPHERYL ACETATE, GLUCONOLACTONE, SODIUM BENZOATE, CANNABIS SATIVA LEAF EXTRACT, VANILLA PLANIFOLIA FRUIT EXTRACT, HELIANTHUS ANNUUS SEED OIL, CETYL ALCOHOL, BENZYL ALCOHOL, DEHYDROACETIC ACID, UBIQUINONE, ALLANTOIN, XANTHAN GUM, SODIUM ASCORBYL PHOSPHATE, PARFUM, LINALOOL, D-LIMONENE, CITRONELLOL, CITRAL, GERANIOL



HEMP EXTRACT  
*Cannabis sativa* L.



WITCH-HAZEL  
LEAF HYDROLATE  
*Hamamelis Virginiana*  
Leaf Water



ARGAN OIL  
*Argania spinosa* L.



SOLUBLE COLLAGEN  
Collagen

# CERTIFICATE OF ANALYSIS No.: 2022-9271

## CLIENT

Pharmahemp d.o.o., Cesta v Gorice 8  
1000 Ljubljana, Slovenija

## SAMPLE \*

CBD MIKKA FIRMING NIGHT CREAM



Sample condition: SUITABLE  
Sample ID: 2224035  
Sample type: Cream  
Batch No.: \* MN00522168A

Work order: 2022-106648  
Analysis ID: 2022\_140  
Method ID: PHL\_RPC\_12C  
Method SOP: MET-LAB-003-02

Sample received: 17/06/2022  
Start of analysis: 17/06/2022  
End of analysis: 20/06/2022  
Analyst: Janez Gerdenc

\* Information provided by the client.

CANNABINOID PROFILE		Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
<b>CBDV</b>	- Cannabidivarin	< LOQ	n/a	_____
<b>CBDA</b>	- Cannabidiolic acid	< LOQ	n/a	_____
<b>CBGA</b>	- Cannabigerolic acid	< LOQ	n/a	_____
<b>CBG</b>	- Cannabigerol	0.0311	0.0093	█_____
<b>CBD</b>	- Cannabidiol	0.489	0.073	██████████_____
<b>THCV</b>	- Tetrahydrocannavarin	< LOQ	n/a	_____
<b>CBN</b>	- Cannabinol	< LOQ	n/a	_____
<b>Δ<sup>9</sup>-THC</b>	- Δ-9-Tetrahydrocannabinol	< LOQ	n/a	_____
<b>Δ<sup>8</sup>-THC</b>	- Δ-8-Tetrahydrocannabinol	< LOQ	n/a	_____
<b>CBL</b>	- Cannabicyclol	< LOQ	n/a	_____
<b>CBC</b>	- Cannabichromene	< LOQ	n/a	_____
<b>Δ<sup>9</sup>-THCA</b>	- Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	_____
<b>CBE</b>	- Cannabielsoin	< LOQ #	n/a	_____
<b>CBNV</b>	- Cannabivarin	< LOQ #	n/a	_____
<b>CBCA</b>	- Cannabichromenic acid	< LOQ #	n/a	_____
<b>CBT</b>	- Cannabicitran	< LOQ #	n/a	_____

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.


The results given herein apply only to the sample as received. Expanded Uncertainty was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

20/06/2022

Approved by:



mag. Marko Dragan  
Analytical Laboratory Manager

Authorized by:



dr. Boštjan Jančar  
Chief Technology Officer

End of Certificate